We are live on ! Find out more
PRLD icon

Prelude Therapeutics
PRLD

70 hedge funds and large institutions have $74M invested in Prelude Therapeutics in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 21 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 7

15% more funds holding

Funds holding: 61 → 70 (+9)

4.18% more ownership

Funds ownership: 80.6% → 84.79% (+4.2%)

0% more call options, than puts

Call options by funds: $1K | Put options by funds: $1K

5% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 21

43% less capital invested

Capital invested by funds: $129M → $74M (-$55.2M)

Holders
70
Holders Change
+9
Holders Change %
+14.75%
% of All Funds
1.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
20
Reduced
21
Closed
7
Calls
$1K
Puts
$1K
Net Calls
–
Net Calls Change
-$3K

Top Buyers

Rank Fund Capital Flow
1
ECM
ExodusPoint Capital Management
New York
+$4.27M
2
APM
Avidity Partners Management
Texas
+$4.12M
3
Marshall Wace
Marshall Wace
United Kingdom
+$1.66M
4
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$1.3M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$955K

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$3.98M
2
DM
Deerfield Management
New York
-$1.7M
3
SCM
Sio Capital Management
New York
-$1.22M
4
KCM
Kennedy Capital Management
Missouri
-$134K
5
Northern Trust
Northern Trust
Illinois
-$84.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$22.6M – – –
BBA
2
Baker Bros. Advisors
New York
$21M – – –
DM
3
Deerfield Management
New York
$7.8M -$1.7M -366,880 -9%
BC
4
Boxer Capital
California
$3.54M -$3.98M -860,100 -33%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$2.27M +$955K +206,301 +23%
BlackRock
6
BlackRock
New York
$2.19M -$49.1K -10,600 -1%
Vanguard Group
7
Vanguard Group
Pennsylvania
$2.12M +$51.9K +11,205 +1%
ECM
8
ExodusPoint Capital Management
New York
$1.91M +$4.27M +921,621 New
APM
9
Avidity Partners Management
Texas
$1.84M +$4.12M +890,000 New
Massachusetts Financial Services
10
Massachusetts Financial Services
Massachusetts
$1.14M +$126K +27,155 +5%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$811K +$138K +29,765 +8%
Marshall Wace
12
Marshall Wace
United Kingdom
$743K +$1.66M +359,137 New
Morgan Stanley
13
Morgan Stanley
New York
$670K +$168K +36,335 +13%
State Street
14
State Street
Massachusetts
$592K +$344K +74,300 +35%
T. Rowe Price Investment Management
15
T. Rowe Price Investment Management
Maryland
$583K +$1.3M +281,583 New
Renaissance Technologies
16
Renaissance Technologies
New York
$408K -$44.9K -9,700 -5%
BCM
17
Bridgeway Capital Management
Texas
$365K +$243K +52,500 +42%
Jacobs Levy Equity Management
18
Jacobs Levy Equity Management
New Jersey
$362K +$728K +157,218 +885%
TD Asset Management
19
TD Asset Management
Ontario, Canada
$341K – – –
Millennium Management
20
Millennium Management
New York
$332K +$743K +160,524 New
Charles Schwab
21
Charles Schwab
California
$276K +$24.2K +5,216 +4%
Northern Trust
22
Northern Trust
Illinois
$220K -$84.8K -18,309 -15%
Goldman Sachs
23
Goldman Sachs
New York
$197K +$93.7K +20,238 +27%
Walleye Capital
24
Walleye Capital
New York
$172K +$315K +67,946 +446%
Acadian Asset Management
25
Acadian Asset Management
Massachusetts
$152K +$241K +52,033 +235%
1
2 3 4

PRLD Hedge Fund Activity: Q3 2024 in Review

70 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q3 2024, worth a combined $74M — down 43% from $129M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new PRLD positions and 7 closed out — a net gain of 9 holders — while 20 added to existing stakes and 21 trimmed.

The largest buyer was ExodusPoint Capital Management, opening a new position worth an estimated $4.27M. The largest seller was Boxer Capital, cutting an estimated $3.98M.

  • 70 institutional investors held Prelude Therapeutics (PRLD) as of Q3 2024, up from 61 in Q2 2024.
  • Funds reported $74M of Prelude Therapeutics stock for Q3 2024, down 43% quarter-over-quarter.
  • 16 funds opened new Prelude Therapeutics positions in Q3 2024 and 7 closed out, a net change of +9 holders.
  • The largest Prelude Therapeutics buyer in Q3 2024 was ExodusPoint Capital Management, an estimated $4.27M added.
  • The largest Prelude Therapeutics seller in Q3 2024 was Boxer Capital, an estimated $3.98M sold.

Based on aggregated 13F filings for Q3 2024.